New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
06:17 EDTCNCCentene sees FY16 adjusted EPS $4.05-$4.40, consensus $4.25
Subscribe for More Information
06:16 EDTCNCCentene reports Q4 EPS 91c, consensus 86c
Subscribe for More Information
February 8, 2016
14:28 EDTCNCNotable companies reporting before tomorrow's open
Subscribe for More Information
11:34 EDTCNCCentene gets contract recommendation for Nebraska's Heritage Health program
Centene announced that its subsidiary, Nebraska Total Care, has been selected by the Nebraska Department of Health and Human Services', DHSS, Division of Medicaid and Long-Term Care as one of three managed care organizations, MCO, to administer its Heritage Health program. Heritage Health is a new healthcare delivery system that combines Nebraska's current physical health, behavioral health, and pharmacy programs into a single comprehensive and coordinated system for 230,000 Medicaid and Children's Health Insurance Program enrollees. Nebraska Total Care has been selected to operate statewide.
February 5, 2016
07:51 EDTALKSWoodford calls Alkermes, Prothena selloffs 'greatly overdone'
British businessman Neil Woodford's Woodford Investment Management said it added to Alkermes (ALKS) and Prothena (PRTA) positions at what it considers to be "extremely attractive valuation levels." In its January letter to investors, the fund says the recent share price moves "look greatly overdone." Woodford also sold its position in GlaxoSmithKline (GSK) and initiated a new stake in Theravance Biopharma (TBPH). The company "retains a valuable economic interest in the future commercial potential of the respiratory franchise being developed in partnership with GlaxoSmithKline," the fund wrote. It also has "some very interesting, albeit earlier-stage, assets in therapeutic areas such as chronic obstructive pulmonary disease, cardiovascular & renal disease," it added. Woodford made no mention of Northwest Biotherapeutics (NWBO) in the letter, a company he invested in last year. Woodford Investment Management, established in 2014, describes itself as the "the opportunity for Neil Woodford, one of the UK's most highly-regarded fund managers, to distil his 30 years of experience and learning into a business founded on his own principles." Reference Link
February 2, 2016
08:59 EDTALKSLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
February 1, 2016
16:11 EDTLMNXLuminex sees Q1 revenue $60M-$62M, consensus $61.9M
Subscribe for More Information
16:10 EDTLMNXLuminex sees FY16 revenue $245M-$255M, consensus $249.13M
Subscribe for More Information
16:10 EDTLMNXLuminex reports Q4 adjusted EPS 56c vs. 19c a year ago
Reports Q4 revenue $60.4M, consensus $60.2M.
10:05 EDTACHCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acadia (ACHC) initiated with an Overweight at KeyBanc... Altisource Residential (RESI) initiated with a Neutral at Nomura... Colony Starwood Homes (SFR) initiated with a Buy at Nomura... EyeGate (EYEG) initiated with a Buy at Rodman & Renshaw... Fortinet (FTNT) initiated with an Outperform at Northland... Halozyme (HALO) initiated with a Buy at Canaccord... Lendingtree (TREE) initiated with an Outperform at Northland... Lindblad Expeditions (LIND) initiated with an Outperform at Credit Suisse... Summit Therapeutics (SMMT) initiated with a Buy at Canaccord... VolitionRx (VNRX) initiated with a Buy at Rodman & Renshaw.
08:58 EDTCNCCentene files to sell 1.14M shares of common stock for RGA International
Subscribe for More Information
08:17 EDTCNCCenturion selected to provide correctional healthcare in Florida
Centene Corporation announced that Centurion of Florida, a JV between Centene and MHM Services, has reached a formal agreement to provide correctional healthcare services for the Florida Department of Corrections in Regions 1, 2 and 3. This agreement with Centurion is a result of the State undertaking negotiation of a gap contract due to early termination by its prior vendor. The initial term of Centurion's contract with the Department of Corrections runs through January 2018 when the Department anticipates completion of a formal procurement. However, the agreement also includes optional renewal periods if the formal procurement is not finalized in the anticipated timeframe. Centurion will provide comprehensive healthcare services to over 70,000 inmates housed at facilities throughout the three Regions.
06:32 EDTACHCAcadia initiated with an Overweight at KeyBanc
Target $85.
January 29, 2016
09:34 EDTACHNAchillion downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
07:59 EDTALKSAlkermes management to meet with JPMorgan
Subscribe for More Information
January 28, 2016
11:33 EDTINCYOptions with increasing call volume
Subscribe for More Information
10:13 EDTALKSOptions with decreasing implied volatility
Subscribe for More Information
08:14 EDTINCYIncyte selloff brings long-term buying opportunity, says Jefferies
Subscribe for More Information
08:08 EDTINCYIncyte selloff a buying opportunity, says Leerink
Leerink analyst Michael Schmidt recommends using today's pullback in shares of Incyte after the company announced its decision to stop one arm of its ongoing Phase II trial of ruxolitinib in metastatic colorectal cancer due to futility as a buying opportunity. The study is one of several ongoing trials to evaluate ruxolitinib in various solid tumor indications, the analyst points out. He says that while the news is disappointing, the stock's current valuation reflects very little if any value for ruxolitinib in solid tumor indications. Schmidt lowered his price target for Incyte shares to $118 from $135 and reiterates an Outperform rating on the name. The stock is down 13%, or $9.98, to $65.01 in pre-market trading.
07:43 EDTINCYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte announced that it would stop a Phase-2 study of Ruxolitinib plus regorafenib for R/R metastatic colorectal cancer and high-CRP patients due to insufficient efficacy, Oppenheimer says the data makes the drug's anti-inflammatory properties in solid tumors questionable. However, the firm did not previously include revenue from the drug outside of pancreatic cancer in its estimates. The firm keeps a $129 price target and Outperform rating on the shares.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use